![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (A.G., E.N.J., M.H.U.); and UCB Société Anonyme, Braine-l'Alleud, Belgium (P.C., R.M.)
The objective of this study was to compare the blood-brain barrier (BBB) transport and brain distribution of levo- (R-CZE) and dextrocetirizine (S-CZE). Microdialysis probes, calibrated using retrodialysis by drug, were placed into the frontal cortex and right jugular vein of eight guinea pigs. Racemic CZE (2.7 mg/kg) was administered as a 60-min i.v. infusion. Unbound and total concentrations of the enantiomers were measured in blood and brain with liquid chromatography-tandem mass spectrometry. The brain distribution of the CZE enantiomers were compared using the parameters Kp, Kp,u, Kp,uu, and Vu,br. Kp compares total brain concentration to total plasma concentration, Kp,u compensates for binding in plasma, whereas Kp,uu also compensates for binding within the brain tissue and directly quantifies the transport across the BBB. Vu,br describes binding within the brain. The stereoselective brain distribution indicated by the Kp of 0.22 and 0.04 for S- and R-CZE, respectively, was caused by different binding to plasma proteins. The transport of the CZE enantiomers across the BBB was not stereoselective, since the Kp,uu was 0.17 and 0.14 (N.S.) for S- and R-CZE, respectively. The Kp,uu values show that the enantiomers are effluxed to a large extent across the BBB. The Vu,br of approximately 2.5 ml/g brain was also similar for both the enantiomers, and the value indicates high binding to brain tissue. Thus, when determining stereoselectivity in brain distribution, it is important to study all factors governing this distribution, binding in blood and brain, and the BBB equilibrium.
This article has been cited by other articles:
![]() |
M. Friden, A. Gupta, M. Antonsson, U. Bredberg, and M. Hammarlund-Udenaes In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids Drug Metab. Dispos., September 1, 2007; 35(9): 1711 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhuang, C. H. Fraga, K. E. Hubbard, N. Hagedorn, J. C. Panetta, C. M. Waters, and C. F. Stewart Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor Cancer Res., December 1, 2006; 66(23): 11305 - 11313. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bostrom, U. S. H. Simonsson, and M. Hammarlund-Udenaes In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics Drug Metab. Dispos., September 1, 2006; 34(9): 1624 - 1631. [Abstract] [Full Text] [PDF] |
||||